Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8008 with bevacizumab/BAT7104 in advanced solid tumors
CTR20242192Phase 2Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BAT8008 in Epithelial Solid Tumor, sponsored by Bio-Thera Solutions, Ltd.. Started Jul 2024; status: terminated.
02
Drugs
BAT8008
03
Conditions
Epithelial Solid Tumor
Beyond the preview
Go deeper on CTR20242192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242192.